PF-219,061

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
PF-219,061
PF-219,061 Structural Formulae.png
Systematic (IUPAC) name
(R)-3-(4-propylmorpholin-2-yl)phenol
Clinical data
Routes of
administration		 Nasal
Identifiers
CAS Number 710654-74-3 YesY
PubChem CID: 9794475
ChemSpider 7970242
Chemical data
Formula C13H19NO2
Molecular mass 221.295 g/mol
  • CCCN1CCO[C@@H](C1)C2=CC(=CC=C2)O
  • InChI=1S/C13H19NO2/c1-2-6-14-7-8-16-13(10-14)11-4-3-5-12(15)9-11/h3-5,9,13,15H,2,6-8,10H2,1H3/t13-/m0/s1
  • Key:WYEGTIGJSHGEID-ZDUSSCGKSA-N
  (verify)

PF-219,061 is a drug developed by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor.[1][2] It is under development as a potential medication for the treatment of female sexual dysfunction.[3][4]

See also

References

  1. ↑ Blagg J, Allerton CM, Batchelor DV, Baxter AD, Burring DJ, Carr CL, Cook AS, Nichols CL, Phipps J, Sanderson VG, Verrier H, Wong S. Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route. Bioorganic and Medicinal Chemistry Letters. 2007 Dec 15;17(24):6691-6. doi:10.1016/j.bmcl.2007.10.059 PMID 17976986
  2. ↑ Brioni JD, Moreland RB. Dopamine D4 receptors and the regulation of penile erection. Drug Discovery Today: Therapeutic Strategies. 2006;3(4):599-604. doi:10.1016/j.ddstr.2006.10.006
  3. ↑ Van Der Graaf et al. SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION. WIPO Patent WO/2003/051370, granted to Pfizer.
  4. ↑ Attkins NJ, Heatherington AC, Phipps J, Verrier H, Huyghe I. Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061. Xenobiotica. 2009 Jul;39(7):523-33. PMID 19480558


Retrieved from "https://infogalactic.com/w/index.php?title=PF-219,061&oldid=1552345"